A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
- Conditions
- ObesityOverweightType 2 Diabetes
- Interventions
- Drug: Placebo
- Registration Number
- NCT06993792
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes. Participants will be screened for about 4 weeks, after which they will enroll into either J2A-MC-GZP1, NCT06972459 (do not have type 2 diabetes) or J2A-MC-GZP2, NCT06972472 (have type 2 diabetes).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 1200
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Orforglipron Dose 1 (Study GZP1) Orforglipron Participants will receive orforglipron orally Orforglipron Dose 2 (Study GZP1) Orforglipron Participants will receive orforglipron orally Orforglipron Dose 3 (Study GZP1) Orforglipron Participants will receive orforglipron orally Orforglipron Dose 4 (Study GZP1) Orforglipron Participants will receive orforglipron orally Placebo (Study GZP1) Placebo Participants will receive placebo orally Orforglipron Dose 1 (Study GZP2) Orforglipron Participants will receive orforglipron orally Orforglipron Dose 2 (Study GZP2) Orforglipron Participants will receive orforglipron orally Orforglipron Dose 3 (Study GZP2) Orforglipron Participants will receive orforglipron orally Orforglipron Dose 4 (Study GZP2) Orforglipron Participants will receive orforglipron orally Placebo (Study GZP2) Placebo Participants will receive placebo orally
- Primary Outcome Measures
Name Time Method Number of Participants Allocated to Each Study Baseline to Week 4
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (89)
Novak Clinical Research - Tucson - North La Cholla Boulevard
🇺🇸Tucson, Arizona, United States
Norcal Endocrinology & Internal Medicine
🇺🇸San Ramon, California, United States
Southern California Clinical Research
🇺🇸Santa Ana, California, United States
Care Access - Thousand Oaks
🇺🇸Thousand Oaks, California, United States
Accel Research Sites - DeLand Clinical Research Unit
🇺🇸DeLand, Florida, United States
Innovation Medical Research Center - Fort Lauderdale
🇺🇸Fort Lauderdale, Florida, United States
Encore Medical Research
🇺🇸Hollywood, Florida, United States
West Orange Endocrinology P.A.
🇺🇸Ocoee, Florida, United States
Care Access - Tampa
🇺🇸Tampa, Florida, United States
Accel Research Sites - NeuroStudies Clinical Research Unit
🇺🇸Decatur, Georgia, United States
Scroll for more (79 remaining)Novak Clinical Research - Tucson - North La Cholla Boulevard🇺🇸Tucson, Arizona, United StatesThili KulatilakePrincipal Investigator